Clearmind Advances Nasal MEAI Formulation For Alcohol Use Disorder

Clearmind Medicine Inc. (Nasdaq: CMND) is taking a meaningful step toward turning its lead compound MEAI into a nasal spray treatment for alcohol use disorder (AUD). The company has completed a formulation feasibility study showing that MEAI can be made into a stable, fully soluble intranasal solution, which is a basic but crucial requirement before testing this delivery route in people.

Why the intranasal milestone matters

The current program is focused on intranasal delivery of MEAI as an additional way to give the drug, starting with AUD. The feasibility work asked two practical questions:

• Can MEAI be combined with a modern intranasal formulation system without breaking down or separating?
• Does it stay fully dissolved and stable in a liquid suitable for nasal spraying?

Clearmind reports that both conditions were met. MEAI can be successfully incorporated into the intranasal formulation, producing a solution that is chemically stable and fully soluble. That matters because a nasal spray needs a smooth, even solution to deliver consistent doses and be comfortable to use. With this hurdle cleared, the company can now move on to refining the formulation and studying how MEAI behaves when absorbed through the nasal passages.

Focus on alcohol use disorder

Alcohol use disorder is a widespread, undertreated condition that affects millions of people and places a heavy burden on families and healthcare systems. Existing medications often offer limited benefit and can be difficult for patients to stick with, which highlights the need for new options.

Clearmind’s intranasal MEAI program aims to improve both effectiveness and real-world use by combining:

• A novel, non-hallucinogenic neuroplastogen (MEAI) designed to reduce compulsive drinking and related behaviors.
• A convenient nasal spray route that could offer faster onset and easier, on-demand dosing, potentially making it simpler for patients to use the treatment consistently.

MEAI’s role and future development

MEAI is Clearmind’s lead proprietary therapeutic candidate for addiction related disorders, including AUD. Early preclinical and clinical work have suggested it may help curb compulsive alcohol consumption while maintaining a favorable safety profile.

By confirming that MEAI works in a nasal formulation, Clearmind strengthens its strategy to develop MEAI as a flexible, multi route therapy rather than a one format drug. The company now has a solid technical base to pursue more detailed formulation optimization and, at a later stage, clinical trials that test whether intranasal MEAI improves outcomes and patient experience compared with traditional routes.

Investor takeaway

For investors, this update is a de risking and positioning story rather than a headline efficacy result:

• It reduces technical risk around a nasal spray version of MEAI by showing the formulation is stable and fully soluble.
• It supports Clearmind’s broader vision of MEAI as a platform drug for addiction, with multiple delivery options that can be tailored to different patient needs.
• It keeps momentum going in a large, under served market (AUD), where better and easier to use treatments could find strong demand if they prove effective.

The usual early stage biotech uncertainties remain. Future clinical results, regulatory timelines, financing and competition will all matter. However, clearing this formulation hurdle is a constructive signal for long term holders watching Clearmind’s progress in addiction focused therapeutics.